Parkinson's Disease Stem Cell Trial
This is a U01NS109463 news story, published by ScienceDaily, that relates primarily to Mass General Brigham news.
U01NS109463 news
For more U01NS109463 news, you can click here:
more U01NS109463 newsmedical innovations news
For more medical innovations news, you can click here:
more medical innovations newsScienceDaily news
For more news from ScienceDaily, you can click here:
more news from ScienceDailyAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like medical innovations news, you might also like this article about
autologous dopamine neuron cell therapy. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest autologous stem cell therapy news, trial reprograms patient news, medical innovations news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Clinically Study Autologous Stem Cell TherapyScienceDaily
•Health
Health
Clinical trial tests novel stem-cell treatment for Parkinson's disease
84% Informative
Phase 1 clinical trial at Mass General Brigham examining safety and feasibility of a groundbreaking treatment approach for Parkinson's disease in which a patient's stem cells are reprogrammed to replace dopamine cells in the brain.
The clinical trial, based on more than three decades of research, has treated three-of-six participants who will be tracked for more than a year .
The autologous transplantation approach circumvents the requirement for immunosuppressive treatments.
The Phase 1 open-label clinical trial will be the first such trial to test blood-derived autologous iPSC-derived dopamine neurons in patients with Parkinson's disease.
The study was supported by a NINDS CREATE Bio grant ( U01NS109463 ).
VR Score
88
Informative language
93
Neutral language
28
Article tone
formal
Language
English
Language complexity
78
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
1
Source diversity
1
Affiliate links
no affiliate links